Phase II randomized trial of neoadjuvant metformin plus letrozole versus placebo plus letrozole for estrogen receptor positive postmenopausal breast cancer (METEOR)

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Kim, Jisun ^a   Lim, Woosung ^b   Kim, Eun Kyu ^c   Kim, Min Kyoon ^d   Paik, Nam Sun ^b   Jeong, Sang Seol ^e   Yoon, Jung han ^f   Park, Chan H ^g   Ahn, Sei H ^a   Kim, Lee S ^h   Han, Sehwan ⁱ   Nam, Seok J ^g   Kang, Han Sung ^j   Kim, Seung I ^k   Yoo, Young B ^l   Jeong, Joon ^k   Kim, Tae H ⁱ   Kang, Taewoo ^m   Kim, Sung Won ⁿ   Jung, Yongsik ^o   Lee, Jeong E ^g   Kim, Ku S ^o   Yu, Jong Han ^a   Chae, Byung J ^e   Jung, So Youn ^a   Kang, Eunyoung ⁿ   Choi, Su Y ^h   Moon, Hyeong Gon ^d,p   Noh, Dong Young ^d,p   Han, Wonshik ^d,p   more..

^a University of Ulsan College of Medicine   (South Korea)

^b Ewha Womans University School of Medicine   (South Korea)

^c Korea Cancer Center Hospital   (South Korea)

^d Seoul National University Hospital   (South Korea)

^e The Catholic University of Korea   (South Korea)

^f Chonnam National University Hwasun Hospital and Medical School   (South Korea)

^g Sungkyunkwan University School of Medicine   (South Korea)

^h Hallym University College of Medicine   (South Korea)

ⁱ Inje University College of Medicine   (South Korea)

^j National Cancer Center   (South Korea)

^k Yonsei University College of Medicine   (South Korea)

^l Konkuk University School of Medicine   (South Korea)

^m Pusan National University School of Medicine   (South Korea)

ⁿ Seoul National University Bundang Hospital   (South Korea)

^o Ajou University School of Medicine   (South Korea)

^p Seoul National University College of Medicine   (South Korea)

more..

Author keywords

Estrogen receptor positive Breast cancer; Letrozole; Metformin; Neoadjuvant

Indexed keywords

KI 67 ANTIGEN; LETROZOLE; METFORMIN; PLACEBO; ESTROGEN RECEPTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INSULIN RECEPTOR; ORGANIC CATION TRANSPORTER 1; S6 KINASE; ANTINEOPLASTIC AGENT; NITRILE; TRIAZOLE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST BIOPSY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CLINICAL EVALUATION; CONTROLLED STUDY; DRUG POTENTIATION; DRUG RESPONSE; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; HUMAN; HUMAN TISSUE; MAMMOGRAPHY; MASTECTOMY; MULTICENTER STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; POSTMENOPAUSE; POSTOPERATIVE PERIOD; PROSPECTIVE STUDY; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; ANTIGEN EXPRESSION; BREAST DENSITY; CANCER SIZE; DNA MICROARRAY; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; NEXT GENERATION SEQUENCING; POSTOPERATIVE CARE; PREOPERATIVE EVALUATION; TRANSLATIONAL RESEARCH; ADJUVANT THERAPY; BREAST NEOPLASMS; CLINICAL PROTOCOL; CLINICAL TRIAL; METABOLISM; METHODOLOGY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CLINICAL PROTOCOLS; FEMALE; HUMANS; METFORMIN; NEOADJUVANT THERAPY; NITRILES; POSTMENOPAUSE; RECEPTORS, ESTROGEN; RESEARCH DESIGN; TRIAZOLES;

EID: 84899135577     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-170     Document Type: Article

References (24)

1. Goodwin PJ, Stambolic V, Lemieux J, Chen BE, Parulekar WR, Gelmon KA, Hershman DL, Hobday TJ, Ligibel JA, Mayer IA, Pritchard KI, Whelan TJ, Rastogi P, Shepherd LE. Evaluation of metformin in early breast cancer: a modification of the traditional paradigm for clinical testing of anti-cancer agents. Breast Cancer Res Treat 2011, 126(1):215-220. 10.1007/s10549-010-1224-1, 20976543.
2. Iliopoulos D, Hirsch HA, Struhl K. Metformin decreases the dose of chemotherapy for prolonging tumor remission in mouse xenografts involving multiple cancer cell types. Can Res 2011, 71(9):3196-3201.
3. Jiralerspong S, Palla SL, Giordano SH, Meric-Bernstam F, Liedtke C, Barnett CM, Hsu L, Hung MC, Hortobagyi GN, Gonzalez-Angulo AM. Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol 2009, 27(20):3297-3302. 10.1200/JCO.2009.19.6410, 2736070, 19487376.
4. Garcia A, Tisman G. Metformin, B(12), and enhanced breast cancer response to chemotherapy. J Clin Oncol 2010, 28(2):e19. author reply e20, 10.1200/JCO.2009.25.7857, 19949002.
5. Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, Wu M, Ventre J, Doebber T, Fujii N, Musi N, Hirshman MF, Goodyear LJ, Moller DE. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001, 108(8):1167-1174. 10.1172/JCI13505, 209533, 11602624.
6. Hawley SA, Gadalla AE, Olsen GS, Hardie DG. The antidiabetic drug metformin activates the AMP-activated protein kinase cascade via an adenine nucleotide-independent mechanism. Diabetes 2002, 51(8):2420-2425. 10.2337/diabetes.51.8.2420, 12145153.
7. Zakikhani M, Dowling R, Fantus IG, Sonenberg N, Pollak M. Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res 2006, 66(21):10269-10273. 10.1158/0008-5472.CAN-06-1500, 17062558.
8. Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 2008, 8(12):915-928. 10.1038/nrc2536, 19029956.
9. Goodwin PJ, Ligibel JA, Stambolic V. Metformin in breast cancer: time for action. J Clin Oncol 2009, 27(20):3271-3273. 10.1200/JCO.2009.22.1630, 19487373.
10. Goodwin PJ, Pritchard KI, Ennis M, Clemons M, Graham M, Fantus IG. Insulin-lowering effects of metformin in women with early breast cancer. Clin Breast Cancer 2008, 8(6):501-505. 10.3816/CBC.2008.n.060, 19073504.
11. Bonanni B, Puntoni M, Cazzaniga M, Pruneri G, Serrano D, Guerrieri-Gonzaga A, Gennari A, Trabacca MS, Galimberti V, Veronesi P, Johansson H, Aristarco V, Bassi F, Luini A, Lazzeroni M, Varricchio C, Viale G, Bruzzi P, Decensi A. Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial. J Clin Oncol 2012, 30(21):2593-2600. 10.1200/JCO.2011.39.3769, 22564993.
12. Martin M, Marais R. Metformin: a diabetes drug for cancer, or a cancer drug for diabetics?. J Clin Oncol 2012, 30(21):2698-2700. 10.1200/JCO.2012.42.1677, 22565000.
13. Semiglazov VF, Semiglazov VV, Dashyan GA, Ziltsova EK, Ivanov VG, Bozhok AA, Melnikova OA, Paltuev RM, Kletzel A, Berstein LM. Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer. Cancer 2007, 110(2):244-254. 10.1002/cncr.22789, 17538978.
14. Mlineritsch B, Tausch C, Singer C, Luschin-Ebengreuth G, Jakesz R, Ploner F, Stierer M, Melbinger E, Menzel C, Urbania A, Fridrik M, Steger G, Wohlmuth P, Gnant M, Greil R Austrian Breast, Colorectal Cancer Study Group(ABCSG) Exemestane as primary systemic treatment for hormone receptor positive post-menopausal breast cancer patients: a phase II trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-17). Breast Cancer Res Treat 2008, 112(1):203-213. 10.1007/s10549-007-9843-x, 18158620, Austrian Breast, Colorectal Cancer Study Group(ABCSG).
15. Eiermann W, Paepke S, Appfelstaedt J, Llombart-Cussac A, Eremin J, Vinholes J, Mauriac L, Ellis M, Lassus M, Chaudri-Ross HA, Dugan M, Borgs M Letrozole Neo-Adjuvant Breast Cancer Study Group Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann Oncol 2001, 12(11):1527-1532. 10.1023/A:1013128213451, 11822750, Letrozole Neo-Adjuvant Breast Cancer Study Group.
16. Baselga J, Semiglazov V, van Dam P, Manikhas A, Bellet M, Mayordomo J, Campone M, Kubista E, Greil R, Bianchi G, Steinseifer J, Mollow B, Tokaji E, Gardner H, Phillips P, Stumm M, Lane HA, Dixon JM, Jonat W, Rugo HS. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol 2009, 27(16):2630-2637. 10.1200/JCO.2008.18.8391, 19380449.
17. Goldenberg N, Glueck CJ, Loftspring M, Sherman A, Wang P. Metformin-diet benefits in women with polycystic ovary syndrome in the bottom and top quintiles for insulin resistance. Metabolism 2005, 54(1):113-121. 10.1016/j.metabol.2004.08.007, 15562389.
18. Ellis MJ, Suman VJ, Hoog J, Lin L, Snider J, Prat A, Parker JS, Luo J, DeSchryver K, Allred DC, Esserman LJ, Unzeitig GW, Margenthaler J, Babiera GV, Marcom PK, Guenther JM, Watson MA, Leitch M, Hunt K, Olson AJ. Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype--ACOSOG Z103. J Clin Oncol 2011, 29(17):2342-2349. 10.1200/JCO.2010.31.6950, 3107749, 21555689.
19. Kim J, Han W, Moon HG, Ahn SK, Shin HC, You JM, Han SW, Im SA, Kim TY, Koo HR, Chang JM, Cho N, Moon WK, Noh DY. Breast density change as a predictive surrogate for response to adjuvant endocrine therapy in hormone receptor positive breast cancer. Breast Cancer Res 2012, 14(4):R102. 10.1186/bcr3221, 3680951, 22770227.
20. Nie K, Chen JH, Chan S, Chau MK, Yu HJ, Bahri S, Tseng T, Nalcioglu O, Su MY. Development of a quantitative method for analysis of breast density based on three-dimensional breast MRI. Med Phys 2008, 35(12):5253-5262. 10.1118/1.3002306, 2673600, 19175084.
21. Huang X, Wullschleger S, Shpiro N, McGuire VA, Sakamoto K, Woods YL, McBurnie W, Fleming S, Alessi DR. Important role of the LKB1-AMPK pathway in suppressing tumorigenesis in PTEN-deficient mice. Biochem J 2008, 412(2):211-221. 10.1042/BJ20080557, 18387000.
22. Anisimov VN, Berstein LM, Egormin PA, Piskunova TS, Popovich IG, Zabezhinski MA, Kovalenko IG, Poroshina TE, Semenchenko AV, Provinciali M, Re F, Franceschi C. Effect of metformin on life span and on the development of spontaneous mammary tumors in HER-2/neu transgenic mice. Exp Gerontol 2005, 40(8-9):685-693.
23. Anisimov VN, Egormin PA, Bershtein LM, Zabezhinskii MA, Piskunova TS, Popovich IG, Semenchenko AV. Metformin decelerates aging and development of mammary tumors in HER-2/neu transgenic mice. Bull Exp Biol Med 2005, 139(6):721-723. 10.1007/s10517-005-0389-9, 16224592.
24. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B American Diabetes A Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009, 32(1):193-203. 10.2337/dc08-9025, 2606813, 18945920, American Diabetes A.